SNP rs16917496 within SETS 3′UTR is associated with the age of onset of breast cancer

Chinese Journal of Oncology

Volumn 34, Issue 11, 2012, Pages 835-837

  Zhang, Bai Lin ^a   Song, Feng Ju ^b   Zheng, Hong ^b   Zhang, Li Na ^b   Zhao, Yan Rui ^b   Chen, Ke Xin ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Breast neoplasms; MicroRNA; SET8 gene; Single nucleotide polymorphism

Indexed keywords

PROTEIN P53; HISTONE LYSINE METHYLTRANSFERASE; MICRORNA; MIRN502 MICRORNA, HUMAN; SETD8 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; BREAST CANCER; CODON; COMPARATIVE STUDY; FEMALE; GENE; GENE INTERACTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; SET8 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BINDING SITE; BREAST TUMOR; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VERY ELDERLY;

3' UNTRANSLATED REGIONS; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BINDING SITES; BREAST NEOPLASMS; CODON; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

MLCS; MLOWN;

EID: 84871517416     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2012.11.008     Document Type: Article

References (15)

1. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J, 2008, 14:1-6.
2. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res, 2008, 68:8535-8540.
3. Ghosh T, Soni K, Scaria V, et al. MicroRNA-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic β-actin gene. Nucleic Acids Res, 2008, 36:6318-6332.
4. Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition. Nat Genet, 2007, 39:1278-1284.
5. Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet, 2008, 82:283-289.
6. Zhu S, Wu H, Wu F, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res, 2008, 18:350-359.
7. Couture JF, Collazo E, Brunzelle JS, et al. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev, 2005, 19:1455-1465.
8. Shi X, Kachirskaia I, Yamaguchi H, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell, 2007, 27:636-646.
9. Song F, He M, Li H, et al. A cancer incidence survey in Tianjin: the third largest city in China between 1981 and 2000. Cancer Causes Control, 2008, 19:443-450.
10. Vazquez A, Bond EE, Levine AJ, et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov, 2008, 7:979-987.
11. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer, 2006, 13:293-325.
12. Papazoglu C, Mills AA. p53: at the crossroad between cancer and ageing. J Pathol, 2007, 211:124-133.
13. Harris SL, Gil G, Hu W, et al. Single-nucleotide polymorphisms in the p53 pathway. Cold Spring Harb Symp Quant Biol, 2005, 70:111-119.
14. Gochhait S, Bukhari SI, Bairwa N, et al. Implication of BRCA2 - 26G > A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res, 2007, 9:R71.
15. 1/S transition by blocking lysine acetylation in histone through binding to H4 N-terminal tail. Cell Cycle, 2008, 7:1423-1432.